Stock MADHAVBAUG VAIDYA SANE AYURVED LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vaidya Sane Ayurved Laboratories Limited

Equities

MADHAVBAUG

INE0JR301013

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:55 2024-06-28 EDT 		5-day change 1st Jan Change
168 INR +5.00% Intraday chart for Vaidya Sane Ayurved Laboratories Limited +5.00% -20.60%
05-26 Vaidya Sane Ayurved Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
05-26 Vaidya Sane Ayurved Laboratories Limited Appoints Narendra Pawar as Chief Financial Officer CI

Valuation

Fiscal Period: March 2022 2023
Capitalization 1 2,050 2,471
Enterprise Value (EV) 1 1,869 2,316
P/E ratio 59.1 x 51.1 x
Yield - 0.21%
Capitalization / Revenue 2.74 x 2.49 x
EV / Revenue 2.5 x 2.34 x
EV / EBITDA 27.2 x 30.4 x
EV / FCF 362,328,729 x -39,718,875 x
FCF Yield 0% -0%
Price to Book 5.71 x 6.11 x
Nbr of stocks (in thousands) 10,513 10,513
Reference price 2 195.0 235.0
Announcement Date 22-06-10 23-07-11
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 376.4 625 752.3 522.7 747.1 991.7
EBITDA 1 23.83 34.44 31.3 43.33 68.68 76.3
EBIT 1 14.41 18.52 11.07 22.11 48.18 52.59
Operating Margin 3.83% 2.96% 1.47% 4.23% 6.45% 5.3%
Earnings before Tax (EBT) 1 14.42 13.58 2.32 16.1 47.49 64.33
Net income 1 10.65 9.719 1.219 15.47 34.69 48.33
Net margin 2.83% 1.56% 0.16% 2.96% 4.64% 4.87%
EPS 2 1.528 1.393 0.1747 2.218 3.299 4.597
Free Cash Flow - -88.97 26.94 40.76 5.158 -58.32
FCF margin - -14.24% 3.58% 7.8% 0.69% -5.88%
FCF Conversion (EBITDA) - - 86.06% 94.07% 7.51% -
FCF Conversion (Net income) - - 2,210.62% 263.5% 14.87% -
Dividend per Share - - - - - 0.5000
Announcement Date 19-09-28 19-09-28 20-12-30 21-12-10 22-06-10 23-07-11
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - 66.1 49.1 1.12 - -
Net Cash position 1 21.1 - - - 181 154
Leverage (Debt/EBITDA) - 1.919 x 1.568 x 0.0257 x - -
Free Cash Flow - -89 26.9 40.8 5.16 -58.3
ROE (net income / shareholders' equity) - 11.1% 1.31% 17.2% 15.2% 12.7%
ROA (Net income/ Total Assets) - 5.09% 2.39% 5.03% 7.77% 6.17%
Assets 1 - 191.1 51.04 307.4 446.5 783.6
Book Value Per Share 2 11.90 13.30 13.40 14.00 34.10 38.50
Cash Flow per Share 2 2.390 1.290 1.520 1.300 2.440 1.680
Capex 1 37.6 89.7 42.2 6.81 31.7 69.8
Capex / Sales 9.98% 14.35% 5.61% 1.3% 4.25% 7.04%
Announcement Date 19-09-28 19-09-28 20-12-30 21-12-10 22-06-10 23-07-11
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Alternative Medicine

1st Jan change Capi.
VAIDYA SANE AYURVED LABORATORIES LIMITED Stock Vaidya Sane Ayurved Laboratories Limited
-20.60% 21.19M
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+26.93% 5.55B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-33.55% 3.52B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
-3.74% 3.03B
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-26.09% 2.59B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-10.93% 2.28B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+41.50% 1.88B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD Stock Zhejiang Jolly Pharmaceutical Co.,LTD
+41.84% 1.46B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
-12.94% 1.43B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK Stock PT Industri Jamu dan Farmasi Sido Muncul Tbk
+47.62% 1.42B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. MADHAVBAUG Stock
  4. Financials Vaidya Sane Ayurved Laboratories Limited